Enovis (NYSE:ENOV) Stock Rating Upgraded by BMO Capital Markets

Enovis (NYSE:ENOV) was upgraded by equities research analysts at BMO Capital Markets to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other brokerages also recently issued reports on ENOV. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enovis in a research note on Wednesday. Wells Fargo & Company decreased their target price on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. William Blair initiated coverage on shares of Enovis in a report on Friday, April 17th. They set an “outperform” rating on the stock. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Monday. Finally, Zacks Research cut shares of Enovis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, Enovis has a consensus rating of “Moderate Buy” and an average price target of $41.71.

Enovis Price Performance

Shares of Enovis stock opened at $25.17 on Wednesday. The stock has a market cap of $1.45 billion, a P/E ratio of -1.27 and a beta of 1.39. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The stock’s fifty day moving average is $23.34 and its 200 day moving average is $23.79. Enovis has a one year low of $19.14 and a one year high of $36.82.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. During the same quarter in the prior year, the business posted $0.81 earnings per share. The business’s quarterly revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts anticipate that Enovis will post 3.12 earnings per share for the current year.

Insider Activity at Enovis

In other news, insider Oliver Engert bought 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the transaction, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders bought 4,200 shares of company stock valued at $92,084 in the last quarter. 2.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Enovis

A number of hedge funds have recently bought and sold shares of the business. Rubric Capital Management LP purchased a new stake in shares of Enovis during the 3rd quarter valued at about $83,435,000. Paradigm Capital Management Inc. NY raised its holdings in shares of Enovis by 70.2% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after buying an additional 732,917 shares during the period. AQR Capital Management LLC lifted its position in shares of Enovis by 682.6% during the second quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock worth $15,627,000 after purchasing an additional 434,646 shares during the last quarter. Front Street Capital Management Inc. lifted its holdings in Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after buying an additional 384,124 shares in the last quarter. Finally, Quantinno Capital Management LP raised its stake in shares of Enovis by 130.8% during the first quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock valued at $13,752,000 after acquiring an additional 342,556 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.